AML
Conditions
Interventions
A:HAG regimen
B:decitabine
Sponsors
Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
60 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed elderly AML is confirmed by bone marrow morphology and immunology assay; 2. APL is excluded by bone marrow morphology or molecular level tests; 3. Patient aged between 60 to 75 years; 4. Patient meets the conditions of Pre-treatment risk assessment stratification scale ("unfit" group) for elderly AML (non-M3); 5. Obtained an Informed Consent Form signed by patient or their families.
Exclusion criteria
Exclusion criteria: 1. APL patients; 2. Re-treated patient; 3. Allergy to any drug presented in study protocol; 4. Obvious contraindications to anthracycline chemotherapy drugs; 5. Patient meets the conditions of "not suitable" and "suitable chemotherapy" in the Pre-treatment risk assessment stratification scale for elderly AML (non-M3); 6. Unable to understand or comply with the study protocol; 7. Previous intolerance or allergy to the similar drugs; 8. Patients below the age of 60 or over 75 (60 and 75 are not included); 9. Participating in other clinical investigation simultaneously; 10. Having any issue that may hinder the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Disease Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete Remission;Early Death Rate;Toxicity and Safety;Minimal residual disease; | — |
Countries
China
Contacts
Public ContactJunmin Li
Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed